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Commentary
It is estimated that over 350 million individuals worldwide are
affected by one of over 7000-8000 rare diseases. International
definitions of rare diseases vary; the definition in the European Union
is a disorder that affects fewer than 5 in 10,000 of the population, and
in the USA it is one that affects fewer than 200,000 individuals.
Collectively these diseases represent a significant global health burden;
the majority is chronically debilitating and life-threatening, and is
without specific treatments. A number of unique challenges are
associated with the clinical development of therapeutics for rare
diseases, including geographically dispersed small patient populations,
phenotypic heterogeneity, incomplete knowledge of the disease
pathophysiology or natural history, limited numbers of experienced
clinical investigators worldwide, regulatory uncertainties and an
absence of prior clinical studies. Additionally, the selection of clinical
trial endpoints, which assess the efficacy of an intervention, and if met
will result in a positive result for the therapy and trial, can be an
arduous process, particularly if validated endpoints appropriate for the
disease are unavailable. Therapeutics developed for rare diseases are
referred to as orphan drugs because under normal market conditions
the pharmaceutical industry would have little interest in developing
drugs intended for a small target population. A number of countries
have introduced orphan drug legislations through which commercial
incentives are provided to the pharmaceutical industry to make rare
disease drug development financially viable; incentives include
marketing exclusivity, protocol assistance and fee reductions. Today,
over 380 orphan designated drugs are commercially available on the
global market and more than 800 are undergoing clinical development.
To expedite the access of patients with unmet needs to novel therapies,
regulatory initiatives exist which have the potential to accelerate
market approval. The USA Food and Drug Administration (FDA)
permits the approval of drugs based on an efficacy evaluation using
surrogate endpoints which are likely to predict clinical benefit [1]. The
European Medicines Agency (EMA) has initiatives such as conditional
marketing authorization, approval under exceptional circumstances
and accelerated assessment [2-4]. In 2016, two collaborative cluster
working groups were established between the EMA and USA FDA. The
focus of the rare disease cluster is to provide information exchange on
topics such as the selection and validation of trial end points, trial
designs in small populations, pre-clinical data evaluation to support
trials, the design of post-marketing studies in the context of early
access initiatives, and risk management strategies for long-term safety
issues [5]. This initiative will complement the patient engagement
cluster which incorporates patient’s involvement and viewpoints in the
drug development process [6]. These collaborative enterprises have the
potential to drive collaborations on a global basis to address the key
challenges that face orphan drug development and provide treatment
accessibility to the rare disease population globally.
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